TabsDetailsBasic DetailsDate Posted: Tuesday, September 15, 2020Status: CompleteMedical Product: sodium-glucose cotransporter-2 (SGLT-2) inhibitorHealth Outcome(s): factors for treatment assignmentDescription: In this request we examined factors related to the initiation of sodium glucose cotransporter-2 inhibitors (SGLT-2i) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) using varying incidence requirements for the definition of initiation in the Sentinel Distributed Database (SDD). Site, demographic, and clinical factors were examined. We estimated odds ratios for the initiation of SGLT-2i over DPP-4i. We also repeated the analyses to compare use of canagliflozin over dapagliflozin, and of canagliflozin over empagliflozin.We distributed this request to eight Sentinel Data Partners on December 3, 2019. The study included data from March 1, 2013 through December 31, 2018.The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation. Read More Deliverables (2)Sentinel Modular Program Report: Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)Sentinel Analytic Package: Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)Additional InformationAdditional DetailsFDA Center: CDERTime Period: March 1, 2013 - December 31, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: ICPE 2020: Factors Related to Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) and Dipeptidyl Peptidase 4 Inhibitor (DPP4i) Dispensing among Naive, Incident, and Prevalent New Users